The cardiovascular and endocrine profile of cromakalim has been studied in 8 healthy men (age 25 +_ 2 years; X SEM) and its influence on renin release from cultured rat juxtaglomerular cells in vitro has also been examined. According to a double-blind, randomized sequence the subjects received placebo or cromakalim t mg as a single daily oral dose for 5 days.
(BP) in animals with certain experimental forms of hypertension [6] , as well as in hypertensive men [7] . The mechanism underlying the cardiovascular response requires further clarification, and the effects of cromakalim on catecholamines and the reninangiotensin-aldosterone system have not been elucidated. Therefore, the first part of the present study was undertaken to investigate the cardiovascular and endocrine profile of cromakalim in normal humans.
The major site of renin production, namely, the renal juxtaglomerular (JG) cell, is a modified vascular smooth muscle cell (VSMC) [8] , and its electrical properties have been found to be identical with VSMC [9] . Experimental evidence suggests that the membrane potential of renal JG epitheloid cells is an important determinant of renin secretion [10, 11] . Considering the hyperpolarizing action of cromakalim on VSCM, the second part of the study was designed to investigate the influence of cromakalim on renin secretion by JG cells in vitro.
Subjects and methods

Studies in humans
Eight healthy non-obese male volunteers, ranging in age from 23 to 27 years (mean (SD), 25 (2) years) were investigated. All had a BP consistently below 140/90 mm Hg, none had evidence of any disease, and none was taking any drugs. Written informed consent was obtained from all subjects.
Cromakalim (Beecham-Wtilfing, FRG), 1 mg, or placebo were administered double-blind in randomized sequence, as a single oral dose each morning for 5 days. The subjects consumed a fixed diet with a daily intake of 130 meq sodium and 75 meq potassium during the 2 study phases, which were separated by an interval of 3 weeks. Alcohol was avoided. The subjects were instructed to maintain their usual physical activity. Possible side-effects of cromakalim were evaluated by a standard self-administered questionnaire, which was completed at the end of each phase. On Day 4 of each study phase, a 24-h urine sample for determination of sodium, potassium and creatinine excretion rates was collected, and body weight was recorded. On Day 5, after overnight fasting, the last capsule was ingested 2 h prior to the following procedure. After an equilibration period of 1 h in the supine position, with a slow intravenous infusion of 5% dextrose solution (6 ml/h), basal BP and heart rate (HR) were measured. Blood samples were taken from an indwelling cannula inserted 30-60 rain previously in the arm contralateral to the infusion, for determination of plasma renin activity (PRA), angiotensin II (ANG II), aldosterone, norepinephrine (NE), epinephrine, dopamine, immunoreactive atrial natrim-etic peptide (irANP), sodium, potassium, calcium and creatinine levels. The basal samples were collected between 08.00 and 08.30 h. The dextrose solution was then replaced by a solution of ANG II (Hypertensin CIBA) in 5% dextrose, which was infused at approximately 2, 4, and 10 ngkg -1. rain-1. During the last 10 rain of each infusion step, BP and HR were recorded every min. At the end of each infusion step blood was collected from the contralaterat arm for determination of PRA, plasma aldosterone, and ANGII. At the last ANGII-infusion step, blood samples for the determination of plasma irANP, sodium and potassium were also collected.
BP was measured with standard cuff and sphygmomanometer; the mean of 3 readings was used for analysis. During the infusion study, BP was monitored with an automatic recorder (Tonoprint SK Grab, Jungingen, FRG); the mean of 9 to 11 measuremerits was used for analysis. Mean arterial BP was calculated as the sum of the diastolic and one-third of the pulse pressure. Plasma and urinary sodium and potassium were measured by flame photometry; calcium and creatinine by Greiner autoanalyser (Greiner SA, Langenthal, Switzerland); PRA, plasma ANGII, aldosterone and irANP by radioimmunoassay [12] [13] [14] [15] and plasma catecholamines by high performance liquid chromatography with electrochemical detection (Waters, Milford, MA: [16] . The methods have been reported previously [17] [18] [19] .
Statistical analysis was performed with the Statistical Analysis System (Version 5,0, Cary, NC, USA). Methods included paired (2-tailed) Student's t-test, regression analysis, and analysis of variance. Since natural logarithmic transformation rather than absolute values followed a Gaussian distribution, the natural logarithms of PRA, ANGII, aldosterone, catecholamine levels and the doses of infused ANGII were used for statistical analysis.
Studies of juxtaglomerular cell cu#ure in vitro
Primary cell cultures of rat JG cells were prepared as single cell suspensions by perifusion of rat kidneys with citrate, dissociation with trypsin and collagenase, and sieving through a 22 ~m screen, as previously described [20, 21] . The cells were further separated on a 25% isoosmotic Percoll gradient, cells with a density of 1.06 g/ml being used for culture. On the second day of culture, about 90% of the attached cells are JG cells, as judged by specific immunostaining for rat renin [21] . Renin release from the cells was measured as the linear increase in renin activity of the supernatant in the absence and presence of cromakalim for 30 rain. The culture medium was replaced with prewarmed, Hepes buffer solution (132 mM NaC1, 5 mM KCI, 0.8 mM MgSO4, 2 mM CaCI2, 10 mM sodium acetate, 2 mM NaH2PO4, 10 mM glucose, 20 mM Hepes, pH 7.2) and the culture dishes were placed on a heating block at 37 ° C. The time-d ependent increase in renin activity in the supernatant was then monitored. Renin activity was determined by its ability to generate angiotensin I from the plasma of bilaterally nephrectomized rats [211. At the end of the experiments, the cells were lysed by addition of 1 N NaOH and cell protein was determined by the method of Lowry [22] .
Results
Studies in humans
Compared with placebo conditions, cromakalim administered orally over 5 days did not significantly modify indices of the electrolyte-fluid volume state, such as body weight, plasma sodium, potassium and calcium levels, 24-h urine sodium and potassium excretion rates, or creatinine clearance (Table 1) ; BP also was unchanged. However, cromakalim produced a significant increase in PRA (+122%, p<0.001), plasma ANGII (+105%, p<0.01), NE (+61%, p<0.01), and heart rate (+8%, p<0.01, while plasma epinephrine, dopamine, aldosterone and irANP levels were unaltered.
During ANGII infusion and treatment either with placebo or cromakalim, the plasma ANGII and 0.70, respectively; p < 0.001), and so was plasma aldosterone (r=0.41 and 0.74, respectively; p<0.05 _v to p < 0.001). The plasma ANGII-BP and ANGII-al-<~ 5-dosterone response curves (Fig. 1) during ANGII infusion were not significantly modified by croma-~ 3 kalim. The mean values of variables measured before and during the final step of the ANGII infusion are shown in Table 2 . The infusion significantly (p<0.01) decreased PRA during administration of Fig.1 . cromakalim, but not during administration of placebo (Fig. 2) . Plasma irANP tended to increase slightly but not significantly during ANGII infusion in both phases of the study.
During administration of cromakalim, 3 subjects complained of slight headache. No other symptoms were noted.
Studies of juxtaglomerular cell cultures
A possible direct effect of cromakalim on renin secretion was assessed on rat renal JG cells. As shown in Fig.3 , cromakalim concentration-dependently stimulated renin secretion from 9.9 (0.9) to 36.6 (2.5) ng AI. h-t-30 rain-rag cell protein (SEM, n=6, p<0.01).
Discussion
The results demonstrate that the presumed K +-channel activator and vasorelaxant cromakalim 1 rag/day for 5 days stimulated the renin-angiotensin system in normal humans and directly activated the release of renin from rat JG cells in vitro. Mechanisms which are known to activate the secretion of renin in humans include an acute fall in BP, salt depletion, enhanced sympathetic discharge [23] , and potassium retention [24] . BP and indices of the electrolyte-fluid volume state here were unchanged and, therefore, could not account for the renin-angiotensin stimulation by cromakalim. Circulating irANP, a potential inhibitor of renin release [20, 25] , also was unaltered. On the other hand, the constellation of increased HR and plasma NE levels during cromakalim treatment is consistent with the possibility that enhanced sympathetic outflow contributed at least in part to activation of the reninangiotensin system in vivo. Considering the vasodilating properties of cromakalim in experimental animals [6] , its effect on plasma NE and heart rate in humans may well be mediated by a baroreflex.
Since basal plasma aldosterone levels were unchanged or were even slightly decreased in the presence of renin-angiotensin stimulation, induced by cromakalim the possibility of an inhibitory inter- Concentration of Cromakalim, pM Effect of cromakalim on renin release from rat juxtaglomerular cell culture. (n=6, Mean (SEM); *p<0.001 vs basal value action of cromakalim with basal aldosterone secretion deserves consideration. However, the responsiveness of aldosterone to ANGII was found not to be altered during administration of cromakalim.
The cromakalim-induced stimulation of renin was blunted during acute hyperangiotensinaemia in the normal humans. This indicates that the physiological feedback inhibition of renin release by ANGII [261 is not impaired by cromakalim. In fact, ANGII infusion during placebo administration, if anything, produced a less distinct and statistically insignificant decrease in PRA, probably due to the lower basal PRA. Previous studies have demonstrated that the degree of renin inhibition during ANGII infusion depends on the pre-infusion PRA level [27] .
The in vitro study revealed that cromakalim was able directly to stimulate JG renin secretion by a mechanism independent of the sympathetic nervous system. Cromakalim has been found to hyperpolarize VSMC by activation of K + channels [2] . Renal JG cells are modified VSMC [8] and have similar electrical properties to those of typical VSMC [9] . Renin release from JG cells is inversely related to the intracellular concentration of calcium [28] . Indirect evidence suggests that voltage-gated calcium channels are involved in the regulation of calcium in JG cells [28] . Thus, it is tempting to speculate that the mechanism of cromakalim-induced renin secretion may perhaps involve hyperpolarisation of JG granular cells.
Although the exact cellular interactions will have to be clarified in future experiments, the in vitro results strongly suggest that a direct action on renal juxtaglomerular cells is a likely explanation for the effect of cromakalim on renin secretion in vivo.
